GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (OTCPK:CFBFF) » Definitions » Cyclically Adjusted PB Ratio

Can Fite Biofarma (Can Fite Biofarma) Cyclically Adjusted PB Ratio : (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Can Fite Biofarma Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Can Fite Biofarma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Can Fite Biofarma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Cyclically Adjusted PB Ratio Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.33 0.25 0.14 0.05

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.05 0.07 0.06 0.05

Competitive Comparison of Can Fite Biofarma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Can Fite Biofarma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Cyclically Adjusted PB Ratio falls into.



Can Fite Biofarma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Can Fite Biofarma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Can Fite Biofarma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.293/129.4194*129.4194
=0.293

Current CPI (Dec. 2023) = 129.4194.

Can Fite Biofarma Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.357 99.695 0.463
201406 0.225 100.560 0.290
201409 0.142 100.428 0.183
201412 0.304 99.070 0.397
201503 0.281 99.621 0.365
201506 0.215 100.684 0.276
201509 0.322 100.392 0.415
201512 0.484 99.792 0.628
201603 0.432 100.470 0.556
201606 0.362 101.688 0.461
201609 0.274 101.861 0.348
201612 0.181 101.863 0.230
201703 0.272 102.862 0.342
201706 0.188 103.349 0.235
201709 0.163 104.136 0.203
201712 0.235 104.011 0.292
201803 0.349 105.290 0.429
201806 0.305 106.317 0.371
201809 0.300 106.507 0.365
201812 0.141 105.998 0.172
201903 0.152 107.251 0.183
201906 0.396 108.070 0.474
201909 0.331 108.329 0.395
201912 0.115 108.420 0.137
202003 0.000 108.902 0.000
202006 0.430 108.767 0.512
202009 0.448 109.815 0.528
202012 0.285 109.897 0.336
202103 0.332 111.754 0.384
202106 0.186 114.631 0.210
202109 0.438 115.734 0.490
202112 0.675 117.630 0.743
202203 0.564 121.301 0.602
202206 0.464 125.017 0.480
202209 0.348 125.227 0.360
202212 0.210 125.222 0.217
202303 0.398 127.348 0.404
202306 0.322 128.729 0.324
202309 0.246 129.860 0.245
202312 0.293 129.419 0.293

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Can Fite Biofarma  (OTCPK:CFBFF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Can Fite Biofarma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019